Blue Jet Healthcare Limited — Q4 FY26 earnings call

Call held 25 May 2026

Management summary

Blue Jet Healthcare reported a mixed Q4 and FY26, with strong growth in the contrast media segment partially offsetting a significant decline in the PI/API business due to customer destocking. The company initiated its large-scale Vizag greenfield expansion and an R&D center in Hyderabad, laying foundations for future growth. Despite a relatively flat FY26 revenue and muted EBITDA, management expressed confidence in FY27 with improved visibility and new product launches, while maintaining a debt-free balance sheet.

Highlights

  • Q4 FY26 Revenue increased by 22% QoQ to INR235 crores, driven by strong momentum in the contrast media segment.

  • Contrast Media segment revenue grew 91% YoY to INR193 crores in Q4 FY26 and 23% YoY to INR495 crores for FY26.

  • Vizag greenfield expansion project commenced, representing a significant long-term growth platform with INR1,000 crores capex planned over 3 years.

  • Company ended FY26 with liquid financial assets of INR400 crores, up from INR306 crores in FY25, and remains debt-free.

  • Improved visibility across several parts of the business, supported by healthy customer engagement in CM and confirmed order visibility in select PI programs for FY27.

Concerns

  • FY26 revenue from operations declined by 8% to INR947 crores compared to FY25.

  • PI/API segment revenue in Q4 FY26 was INR2.4 crores, significantly down from INR40 crores in Q3 and INR196 crores in Q4 FY25, primarily due to customer destocking.

  • FY26 EBITDA was muted at 31% compared to 37% in FY25, impacted by lower volumes in the PI/API category.

  • FY26 PAT stood at 26% compared to 30% in FY25.

  • Logistics costs post March '26 have increased, and their impact in FY27 needs to be evaluated.

Key financials

2 periods

Q4 FY26

  • Revenue
    ₹235 Cr
    YoY -31% QoQ +22%
  • Gross Margin
    56%

FY26

  • Revenue
    ₹947 Cr
    YoY -8%
  • Gross Margin
    54%
  • EBITDA
    31%
  • PAT
    26%

What they filed

Q1 FY27: revenue down 17.5%, net profit down 14.3% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue208 318 340 355 165 −21%192 −40%235 −31%293 −17%
EBITDA69 124 140 121 55 −20%47 −62%71 −49%98 −19%
Net profit58 99 110 91 52 −10%40 −60%64 −42%78 −14%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

Share of Revenue (Q4 FY26)
₹232.4 Cr Total
  • Contrast Media ₹193 Cr 83.0%
  • Artificial Sweetener ₹37 Cr 15.9%
  • PI/API ₹2.4 Cr 1.0%

Capital allocation

high confidence
  • Capex ₹400 Cr
    • Vizag greenfield project
    • Completion of Mahad facility
    • Additions in Ambernath
    We propose to spend approximately INR400 crores in FY27 towards Vizag greenfield, completion of Mahad and other additions in Ambernath.
  • Debt Debt disclosed
    As on year-end, we are a debt-free company.
  • Liquidity Cash ₹400 Cr Liquid financial assets at FY26 end, up from INR306 crores in FY25.
    We ended FY26 with liquid financial assets of INR400 crores as against INR306 crores in FY25.

Guidance & targets

Capex

  • Vizag Greenfield Project Total Capex Capex · over a period of approximately 3 years · High confidence INR1,000 crores
    The total capex that we envisage for the Vizag project is approximately INR1,000 crores over a period of approximately 3 years.

    — VK Singh

  • Hyderabad R&D Center Investment Capex · High confidence INR40 crores
    Our upcoming R&D center in Hyderabad with a planned investment of about INR40 crores will focus on newer chemistry platforms...

    — VK Singh

  • FY27 Capex Plan Capex · FY27 · High confidence INR400 crores
    We propose to spend approximately INR400 crores in FY27 towards Vizag greenfield, completion of Mahad and other additions in Ambernath.

    — Ganesh Karuppannan

Revenue Growth

  • Contrast Media Segment Annual Forecast Revenue Growth · FY27 · Medium confidence mid-single digit growth
    Annual forecast from the customer has a mid-single digit growth for FY27.

    — Ganesh Karuppannan

  • NCE Molecule Commercialized in FY25 Performance Revenue Growth · near term · Medium confidence positive momentum
    Based on the current forecast, we expect this category will continue to have a positive momentum in FY27.

    — Ganesh Karuppannan

  • Overall Revenue Growth Revenue Growth · FY27 · Medium confidence double-digit growth
    And we should be in a position to with a couple of new launches we are expecting, we do expect 1 or 2 validations and 1 commercial launch, which should actually like ensure that we will actually get into a sort of double-digit growth. That's what we are expecting.

    — Ganesh Karuppannan

Capacity

  • Vizag Capacity Online Timeline Capacity · High confidence 24 to 30 months
    And we envisage 24 to 30 months for that capacity to get online.

    — VK Singh

Energy Consumption

  • Renewable Energy Share Energy Consumption · Today · High confidence 70%
    Today, close to 70% of our energy consumption is supported through renewables...

    — VK Singh

What to watch in Q1 FY27

PI segment recovery and order visibility

next quarter
Current Impacted by destocking in FY26
Target Improved visibility and good set of numbers

Why it matters

The PI segment saw a significant decline in FY26; its recovery is crucial for overall growth.

So we are quite confident that in the PI segment, we are getting to a very good set of numbers in the coming year.

Risks & concerns

  • Customer side inventory normalization in PI/API segment

    high

    Impacted PI/API business, leading to a significant revenue decline in FY26.

    Management acknowledged

  • Raw material price increase due to geopolitical situation

    medium

    Happened in the last month of FY26 due to Iran war, negated by rupee depreciation.

    Management acknowledged

  • Increased logistics costs

    medium

    Post March '26, logistics costs have increased and will need evaluation for FY27.

    Management acknowledged

  • Faster price erosion in peptide segment

    medium

    Compared to other segments, peptides could see faster price erosion despite good initial margins.

    Management acknowledged

  • Impact of crude oil price on chemicals and logistics

    medium

    Crude oil price impact on chemicals and logistics costs, with a potential 'domino effect' not fully seen yet.

    Management acknowledged

Q&A highlights

6 direct
Confidence in PI segment recovery and new product launches Direct
On the PI part, Sanjesh, we are gaining confidence because whatever inventory had been built up, so that inventory, the destocking has happened. So if you recall, last time we said that the orders were already in our hand, but the supplies were deferred. So that was one part. Subsequent to the supply chain realignment, we have some more orders with us. So we are quite confident that in the PI segment, we are getting to a very good set of numbers in the coming year.

Addresses the significant decline in the PI segment and provides management's rationale for expected recovery and future growth.

Asked by Sanjesh, ICICI Securities

Lateral entry products and dedicated capacity at Vizag Partial
So Sanjesh, I think all that we can say right now is that we have very high conviction on those lateral entries, and that's the reason that we are mentioning specifically only 2. And they will take a while to fructify. Then as and when they happen, there will be significant opportunities. And that's the reason that we are looking at putting -- deploying dedicated capacity at Vizag for that.

Highlights strategic focus on high-conviction lateral entries and their long-term capacity planning at Vizag, despite not revealing product specifics.

Asked by Sanjesh, ICICI Securities

Peptides strategy and lab supplies Direct
So we are with a couple of these GLP innovators, but not for the end peptide, but for the building blocks, for the intermediates of the peptides. ... Yes. We have started lab supplies to some innovators and we have also started some lab supplies to some very large peptide CDMOS.

Clarifies the company's entry point into the peptide segment (building blocks/intermediates) and confirms initial lab supply activities, indicating pipeline progress.

Asked by Sanjesh, ICICI Securities

Contrast media Q4 growth drivers and FY27 outlook Direct
See, if you look at Q4, majority of the turnover is from the existing customer, existing product, okay? When you look at FY27, whatever we have marketed, we have got -- the forecast is quite encouraging. And we should be in a position to with a couple of new launches we are expecting, we do expect 1 or 2 validations and 1 commercial launch, which should actually like ensure that we will actually get into a sort of double-digit growth. That's what we are expecting.

Explains the source of Q4 growth and provides a clear outlook for FY27 contrast media, including new launches and double-digit growth expectations.

Asked by Pritesh Chheda, Lucky Investments

Margin outlook for next fiscal year given geopolitical scenario and cost pressures Partial
Actually, the cost structures are evolving. We need to actually watch how the Q1 cost structures pan out. We will be in a better position to talk about it during the Q1 results. ... See, you know the impact of crude oil price, which has actually impacted most of the chemicals, logistics cost, and there is also going to be a domino effect, okay? Today, whatever we saw in the month of March '26 was very limited. The impact was not fully seen for many of these companies.

Highlights the uncertainty around margin trajectory due to evolving cost structures and geopolitical impacts, deferring a clear outlook to Q1 results.

Asked by Samitinjoy Basak, Kotak Institutional Equities

Impact of customer's warning letter on supply Direct
See, Ritika, we know only as much is there in the public domain. And even if we would have more information, let us say, just in case we did, it's a very sensitive matter and we will not be able to talk about these things on this open call. But then as you have yourself very rightly said that they yet do not have an import alert, so which means that the commercial impact should not be there till the time there's an import alert. ... From my side, I think it's business as usual in this particular segment. And we don't see foresee any disruption in the coming quarters also.

Addresses a potential risk from a customer's regulatory issue, reassuring that there's no immediate supply disruption and it's business as usual.

Asked by Ritika Agarwal, ValueQuest

Peptide segment margins and price erosion Direct
The margins will be very good, in line or better than what we have. But then you must understand that as compared to the other segments, there could be faster, higher price erosion in this segment. In contrast media and the patented CDMO segment, we don't have that type of price erosion, which perhaps we may see in the peptide segment.

Provides insight into the expected margin profile of the peptide segment, noting good margins but also a potential for faster price erosion compared to other segments.

Asked by Dheeraj Kumar Reddy, Alpha Square

Pharma intermediates and API segment outlook Direct
Keshav, we don't really give guidances. But then all that we will say is that whatever destocking had to happen has happened, and the plant has been now running to optimum capacity and the shipments have started rolling out. And you will soon see that in the data. ... Absolutely. That's a good summary.

Confirms that the worst of the destocking in the PI/API segment is over and plants are running at optimum capacity, signaling a recovery.

Asked by Keshav Bagdi, Vedhant Fashion Family Office

3 min read 6 chapters

Detailed narrative

Q4 and FY26 Performance Overview

Blue Jet Healthcare reported Q4 FY26 revenue of INR235 crores, marking a 22% sequential increase but a 31% year-over-year decline. For the full fiscal year 2026, revenue from operations stood at INR947 crores, an 8% decrease compared to FY25. Gross margin for Q4 FY26 was 56%, up from 52% in Q3, while the full-year gross margin was 54% (down from 55% in FY25). FY26 EBITDA was 31% (vs 37% in FY25), and PAT was 26% (vs 30% in FY25), primarily impacted by lower volumes in the PI/API segment.

Segmental Performance: Contrast Media Leads Growth

The Contrast Media segment demonstrated strong momentum, with Q4 FY26 revenue surging 91% YoY to INR193 crores and 55% QoQ. For FY26, this segment grew 23% YoY to INR495 crores. In contrast, the PI/API segment faced significant headwinds due to customer destocking, resulting in Q4 FY26 revenue of only INR2.4 crores, a sharp drop from INR196 crores in Q4 FY25. The full-year PI/API revenue declined 35% to INR298 crores. The Artificial Sweetener segment saw Q4 revenue of INR37 crores (up 43% QoQ) but a 24% YoY decline, with FY26 revenue down 2% to INR131 crores due to pricing pressure.

Strategic Investments and Capacity Expansion

A key highlight was the commencement of the Vizag greenfield expansion project, which is envisaged to cost approximately INR1,000 crores over three years. This facility will develop dedicated manufacturing blocks for contrast media intermediates, high-intensity sweeteners, and pharma intermediates, with capacity expected to come online in 24-30 months. Additionally, the Mahad Unit 3 site is progressing well on backward integration for key raw materials and is expected to start production in H2 FY27. The company also plans to invest INR40 crores in an R&D center in Hyderabad, focusing on new chemistry platforms like peptides and biocatalysts.

Future Growth Drivers and Pipeline

Management expressed confidence in FY27, anticipating improved visibility and double-digit growth, supported by new product launches and healthy customer engagement in the contrast media segment. The PI/API segment is expected to normalize as destocking is complete, with new orders in hand. The company is tracking approximately 20 active RFPs in the PI/CDMO segment, with two opportunities expected to move to commercialization in the current year. Two high-conviction commercial-stage opportunities are also being evaluated for strategic lateral entries, with dedicated capacity factored into Vizag planning.

Operational Efficiency and Sustainability

Blue Jet Healthcare continues its focus on sustainability, with close to 70% of its energy consumption supported by renewables. The company was awarded the CII National Award for Excellence in Energy Management. While rupee depreciation in FY26 helped negate raw material price increases, the impact of rising crude oil prices and logistics costs post March '26 will need careful evaluation in FY27, potentially affecting cost structures and margins.

Capital Allocation and Financial Health

The company maintains a strong financial position, ending FY26 as a debt-free entity. Liquid financial assets increased to INR400 crores at FY26 end, up from INR306 crores in FY25. Cash flow from operating activities stood at INR334 crores. For FY27, the company plans a capex of approximately INR400 crores, allocated towards the Vizag greenfield project, completion of Mahad, and additions in Ambernath, aligning investments with customer engagement and future product opportunities.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls